Medical device companies will continue to spin off and sell assets to improve their financials and increase their focus on core activities, Moody’s Ratings analysts said in a report. A series of companies including 3M and Zimmer Biomet have recently spun off assets, and analysts predict the trend will continue, starting with Baxter and Edwards Lifesciences deals that are expected to close this year. The analysts said tuck-in acquisitions in high-growth, high-margin areas will remain the focus for M&A, but they see potential for larger deals if interest rates fall significantly.
Read the full article: Spinoffs, Sales and Tuck-Ins Top Medtech Deal Priorities: Moody’s //
Source: https://www.medtechdive.com/news/spin-offs-sales-medtech-deals-moodys/713686